scholarly journals Heterotypic Neuraminidase Antibodies Against Different A(H1N1) Strains are Elicited after Seasonal Influenza Vaccination

Vaccines ◽  
2019 ◽  
Vol 7 (1) ◽  
pp. 30 ◽  
Author(s):  
Jose Mendez-Legaza ◽  
Raúl Ortiz de Lejarazu ◽  
Ivan Sanz
Keyword(s):  
Immune Response ◽  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Geometric Mean ◽  
Age Groups ◽  
Influenza Vaccines ◽  
Serum Samples ◽  
Seasonal Influenza Vaccination ◽  
Before And After ◽  
Original Antigenic Sin

Neuraminidase (NA) content is not standardized in current seasonal influenza vaccines; neither anti-NA antibodies (anti-NA Abs) are measured nor is it well-defined as a correlate of humoral protection. In this work, the presence of NA1 antibodies against classical A(H1N1) and A(H1N1) pdm09 subtypes was studied before and after vaccination with seasonal vaccines containing A/California/07/2009 strain (A(H1N1) pdm09 subtype). By Enzyme-Linked Lectin Assay (ELLA; Consortium for the Standardization of Influenza Seroepidemiology), we analyzed serum samples from two different cohorts (adults and elderly). The presence of anti-NA Abs at titers ≥1/40 against classical A(H1N1) and A(H1N1) pdm09 subtypes were frequently found in both age groups, in 81.3% and 96.3% of adults and elderly, respectively. The higher titers of anti-NA Abs (NAI titers) were detected more frequently against classical A(H1N1) strains according to the expected age when the first flu infection takes place. In this way, an Original Antigenic Sin phenomenon related to NA seems to be part of the immune response against flu. Seasonal-vaccination induced homologous seroconversion against NA of A(H1N1) pdm09 subtype in 52.5% and 55.0%, and increased the Geometric Mean Titers (GMTs) in 70.0% and 78.8% of adults and elderly, respectively. Seasonal vaccination also induced a heterotypic anti-NA Abs response against classical A(H1N1) strains (seroconversion at least in 8.8% and 11.3% of adults and elderly, respectively, and an increase in GMTs of at least 28.0% in both age groups). These anti-NA Abs responses occur even though the seasonal vaccine does not contain a standardized amount of NA. This work demonstrates that seasonal vaccines containing the A(H1N1) pdm09 subtype induce a broad antibody response against NA1, that may be a target for future influenza vaccines. Our study is one of the first to analyze the presence of Abs against NA and the response mediated by NAI titers after seasonal influenza vaccination.

scholarly journals The Effects of Imprinting and Repeated Seasonal Influenza Vaccination on Adaptive Immunity after Influenza Vaccination

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 663
Author(s):  
Amy C. Sherman ◽  
Lilin Lai ◽  
Mary Bower ◽  
Muktha S. Natrajan ◽  
Christopher Huerta ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Geometric Mean ◽  
Fold Change ◽  
Post Vaccination ◽  
Seasonal Influenza Vaccination ◽  
Vaccine Responses ◽  
Immune Factors ◽  
Antibody Secreting Cells

(1) Background: The influenza virus continues to cause significant annual morbidity and mortality. The overall efficacy of seasonal influenza vaccination is suboptimal, which is partly due to host immune factors. The effects of imprinting and repeated seasonal influenza vaccination were investigated to assess for immune factors and mechanisms that impact influenza vaccine responses. (2) Methods: Twenty participants were enrolled into a prospective pilot study based on birth cohort and seasonal influenza immunization history. Immunologic parameters were assessed over a six-month period after the seasonal influenza vaccine was administered. (3) Results: There was no significant imprinting effect, as measured by hemagglutination inhibition (HAI) fold change, HAI geometric mean titer (GMT) for Day 29 or Day 180 post-vaccination and antigen- specific antibody-secreting cells (ASC) for Day 8 post-vaccination. Individuals who had minimal prior seasonal influenza vaccination had a higher magnitude ASC response and a higher HAI fold change post-vaccination than individuals who were repeatedly vaccinated. (4) Conclusions: Repeated seasonal influenza vaccination resulted in a decreased fold change of the immune response, although individuals in this cohort tended to have high HAI titers at baseline that persisted after vaccination. Imprinting effects were not observed in this cohort. These host immune factors should be considered in the development of universal influenza vaccines. ClinicalTrials.gov Identifier: NCT03686514.

scholarly journals Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination

2016 ◽  
Vol 22 (12) ◽  
pp. 1456-1464 ◽  
Author(s):  
Jiwon Lee ◽  
Daniel R Boutz ◽  
Veronika Chromikova ◽  
M Gordon Joyce ◽  
Christopher Vollmers ◽  
...  
Keyword(s):  
Young Adults ◽  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Molecular Level ◽  
Serum Antibody ◽  
Antibody Repertoire ◽  
Seasonal Influenza Vaccination ◽  
Before And After ◽  
Level Analysis

scholarly journals Community pharmacist-administered seasonal influenza vaccination: a national customer survey

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Dominik Stämpfli ◽  
Adrian Martinez-De la Torre ◽  
Sophie Du Pasquier ◽  
Danielle Stegmann ◽  
Andrea Brügger ◽  
...  
Keyword(s):  
High Risk ◽  
Influenza Vaccination ◽  
Community Pharmacist ◽  
Seasonal Influenza ◽  
Age Groups ◽  
Risk Groups ◽  
Injection Technique ◽  
Equal Distribution ◽  
Seasonal Influenza Vaccination ◽  
Influenza Vaccinations

Abstract Background In Switzerland, the influenza vaccination is recommended for high-risk groups and people who have contact with high-risk groups. Since 2015, Swiss pharmacists are allowed to vaccinate healthy adults after acquiring a certificate of competence for vaccination and blood sampling techniques. We aimed to assess customers of the seasonal influenza vaccination in pharmacies in regard to their satisfaction, motivation, and reasons. Methods Swiss pharmacies collected survey data during a period of 12 weeks from mid-October 2019 to mid-January 2020. Each participating pharmacy was sent 20 questionnaires to be handed out to vaccinated customers. The questionnaire was available in German and French and subdivided into four sections: demographic information, satisfaction, reasons for getting the vaccination, and reasons for choosing a pharmacy as a place of vaccination. We tested for statistical differences in answer tendencies across strata on questionnaire language, age groups, and levels of education. Results Of the 1600 surveys sent, 80 pharmacies sent back 656 completed questionnaires (return rate, 41%). Main age bracket was 65–74 years (26.2%), followed by 55–64 years (24.7%), with an equal distribution of reported sex (female, 49.5%). Of the respondents, 99% would have recommended the service and 88.5% felt very comfortable being vaccinated by a pharmacist. Satisfaction included injection technique, used facilities, preparatory discussions, and pricing of the service. Easy scheduling was a main motivation for choosing a pharmacy as the vaccination provider. We identified minor differences in answer tendencies across questionnaire language and age groups, but not across levels of education. Conclusion Customer satisfaction with community pharmacist-administered seasonal influenza vaccinations is high in Switzerland.

scholarly journals Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach

2012 ◽  
Vol 11 (8) ◽  
pp. 985-994 ◽  
Author(s):  
Nathaniel D Lambert ◽  
Inna G Ovsyannikova ◽  
V Shane Pankratz ◽  
Robert M Jacobson ◽  
Gregory A Poland
Keyword(s):  
Older Adults ◽  
Immune Response ◽  
Systems Biology ◽  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Seasonal Influenza Vaccination

scholarly journals Impact of ageing and a synbiotic on the immune response to seasonal influenza vaccination; a randomised controlled trial

2018 ◽  
Vol 37 (2) ◽  
pp. 443-451 ◽  
Author(s):  
Sumia Enani ◽  
Agnieszka Przemska-Kosicka ◽  
Caroline E. Childs ◽  
Catherine Maidens ◽  
Honglin Dong ◽  
...  
Keyword(s):  
Immune Response ◽  
Randomised Controlled Trial ◽  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Controlled Trial ◽  
Seasonal Influenza Vaccination ◽  
Randomised Controlled

scholarly journals Influenza B Lineages Have More in Common Than Meets the Eye. Trivalent Influenza Vaccines Trigger Heterotypic Antibodies Against Both Influenza B Viruses

2021 ◽  
Vol 12 ◽  
Author(s):  
Laura Sánchez-de Prada ◽  
Silvia Rojo-Rello ◽  
Marta Domínguez-Gil ◽  
Eduardo Tamayo-Gómez ◽  
Raúl Ortiz de Lejarazu-Leonardo ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Seasonal Influenza ◽  
The Elderly ◽  
Cross Reactivity ◽  
Influenza Vaccines ◽  
Influenza B ◽  
Relevant Factor ◽  
Serum Samples ◽  
Trivalent Influenza Vaccine ◽  
Before And After

Influenza B is accountable for an important burden during flu epidemics, causing special impact in children and the elderly. Vaccination is the best approach to address influenza infections. However, one of the main problems of this virus is that two different lineages circulate together, Victoria and Yamagata; and trivalent vaccines, that only contain one of these lineages, are still in use. For that reason, if during an epidemic, the lineage not included in the vaccine predominates, a mismatch would occur, and the vaccine effectiveness will be very poor. In this work, we evaluated the cross-protection given by the trivalent Influenza vaccine and compared serological profiles based on age, sex, and the type of vaccine used. We performed a retrospective analysis of serum samples obtained before and after seasonal influenza vaccination during 20 seasons (1998–2018). The results showed that heterotypic reactivity between both influenza B lineages is common, but always lower than the homologous response. Age is a relevant factor for this cross-reactivity between both lineages, while the sex and the type of vaccine not. Vaccination with trivalent influenza vaccines elicits cross-reactive antibodies against both lineages, however, this response might not be enough to provide an appropriate serological protection in case of mismatch.

scholarly journals Optimising age coverage of seasonal influenza vaccination in England: A mathematical and health economic evaluation

2020 ◽  
Author(s):  
Edward M. Hill ◽  
Stavros Petrou ◽  
Henry Forster ◽  
Simon de Lusignan ◽  
Ivelina Yonova ◽  
...  
Keyword(s):  
Health Economic ◽  
At Risk ◽  
Cost Effectiveness ◽  
Influenza Vaccination ◽  
Seasonal Influenza ◽  
Age Groups ◽  
Cost Effective ◽  
Low Risk ◽  
Transmission Dynamics ◽  
Seasonal Influenza Vaccination

AbstractFor infectious disease prevention, policy-makers are typically required to base policy decisions in light of operational and monetary restrictions, prohibiting implementation of all candidate interventions. To inform the evidence-base underpinning policy decision making, mathematical and health economic modelling can be a valuable constituent. Applied to England, this study aims to identify the optimal target age groups when extending a seasonal influenza vaccination programme of at-risk individuals to those individuals at low risk of developing complications following infection. To perform this analysis, we utilise an age- and strain-structured transmission model that includes immunity propagation mechanisms which link prior season epidemiological outcomes to immunity at the beginning of the following season. Making use of surveillance data from the past decade in conjunction with our dynamic model, we simulate transmission dynamics of seasonal influenza in England from 2012 to 2018. We infer that modified susceptibility due to natural infection in the previous influenza season is the only immunity propagation mechanism to deliver a non-negligible impact on the transmission dynamics. Further, we discerned case ascertainment to be higher for young infants compared to adults under 65 years old, and uncovered a decrease in case ascertainment as age increased from 65 to 85 years of age. Our health economic appraisal sweeps vaccination age space to determine threshold vaccine dose prices achieving cost-effectiveness under differing paired strategies. In particular, we model offering vaccination to all those low-risk individuals younger than a given age (but no younger than two years old) and all low-risk individuals older than a given age, while maintaining vaccination of at-risk individuals of any age. All posited strategies were deemed cost-effective. In general, the addition of low-risk vaccination programmes whose coverage encompassed children and young adults (aged 20 and below) were highly cost-effective. The inclusion of old age-groups to the low-risk programme typically lessened the cost-effectiveness. Notably, elderly-centric programmes vaccinating from 65-75 years and above had the least permitted expense per vaccine.

Sign in / Sign up

Export Citation Format

Share Document